GPNMB and frontotemporal dementia: The aim of this study is to assess the effects of GPNMB knock-down via antisense oligonucleotides (ASOs) on both lysosomal function and immune cell responses in peripheral macrophages from 5-to-6-month-old Grn -/- mice and PBMCs from FTD-GRN patients to establish a functional proof of concept on whether GPNMB-targeting therapies would be deleterious or beneficial in the context of FTD-GRN.